Navigation Links
PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting

VIENNA, Austria and NES-ZIONA, Israel, Sept. 13, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that researchers at ENEA 2012, the 15th Annual Congress of the European NeuroEndocrine Association, will present data from the company's Phase II trial of its long acting human growth hormone, hGH-CTP, in growth hormone deficient adults.  The data, which were previously reported by the company, confirm that hGH-CTP has the potential to be administered once weekly to adults with growth hormone deficiency and that it appears to be safe and well tolerated.  ENEA 2012 is being held September 12-15, 2012 in Vienna, Austria.

Dr. Abraham Havron, CEO of PROLOR commented, "As we move forward with the manufacturing, regulatory and clinical activities required to enter Phase III trials, we welcome the opportunity to share our positive hGH-CTP data with relevant global opinion leaders, such as those attending ENEA 2012, a biennial meeting that brings together prominent neuroendocrine researchers and clinicians to discuss important developments in the field."

The data to be presented include results from the company's Phase II trial, which administered hGH-CTP to growth hormone deficient adults for four weeks, as well as results from a 16-week treatment extension study of hGH-CTP in a similar population.  These data affirmed that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed human growth hormone, and at a much lower cumulative dose, further validating the dosing regimen for the company's upcoming Phase III trial.  An exploratory part of the study also demonstrated the potential for a twice-monthly injection regimen.  hGH-CTP demonstrated a good safety and tolerability profile in these studies, with no unexpected adverse events.

Poster 197, Once-Weekly, CTP-Modified hGH (MOD-4023) Is Effective in Growth Hormone Deficient Adults: A Phase II Dose and Frequency Finding Study, will be presented during the September 14, 2012 poster session.  For more information, visit

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is currently developing a long-acting version of human growth hormone, which successfully completed a Phase II clinical trial.  It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.  For more information, visit

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.PROLOR CONTACT:MEDIA CONTACT:Shai Novik, PresidentBarbara LindheimPROLOR Biotech, Inc.BLL Partners, LLCTel: +1 866 644-78+1 212  

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
2. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
3. Why Texas is #1 in Business: Local BioTech Company Expands
4. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
5. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
6. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
7. Biomass characterization technology research highlighted in Industrial Biotechnology journal
8. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
9. Global Marine Biotechnology Industry
10. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
11. India Biotechnology in India Industry
Post Your Comments:
(Date:10/13/2015)... New York , October 13, 2015 ... Growth, Trends, and Forecast 2015 - 2023 " , ... in 2014 and is anticipated to reach US$7.59 bn by 2023, ... 2015 to 2023. --> " Microbiology Culture Market ... - 2023 " , the global microbiology culture ...
(Date:10/13/2015)... October 13, 2015 TapImmune, Inc. ... development of innovative peptide and gene-based immunotherapeutics and vaccines ... be a featured presenting company at the Dawson ... Grand Hotel in Jupiter, Florida ... (TPIV), a clinical-stage immunotherapy company specializing in the ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... ultrasound (HIFU) technologies, announced today that it received de novo clearance from the ... the U.S. for the ablation of prostate tissue. Sonablate® is the first High ...
(Date:10/12/2015)... ... October 12, 2015 , ... Spirax Sarco, the leader ... of the CSM-C 600 compact clean steam generator . This unit is ... the requirements of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 generator can ...
Breaking Biology Technology:
(Date:9/10/2015)... Sept. 10, 2015 Report Details ... Reveals Selling Opportunities and Revenue Prospects to Help ... of biologics, especially new drug classes? Get the ... ahead with exclusive market data and industry knowledge, ... developments, results, opportunities and sales predictions. Visiongain,s ...
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant ... Clinic Wellness to create an interactive, image-based health ... health and wellness kiosk.  The unique assessment quantifies ... a number that suggests an individual,s biological age ... values as measured by the kiosk. ...
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security announced ... solution-based milestones, furthering the company,s commitment to protecting ... fraud. NuData Security,s online fraud detection ... company,s growth cycle. The product combines continual analysis ... good user behavior from fraudulent behavior, allowing the ...
Breaking Biology News(10 mins):